Arch Therapeutics Inc is a pioneering medical device company that prioritizes patient health and safety. With an unwavering commitment to advancing technology, Arch Therapeutics Inc focuses on developing innovative solutions for surgical and therapeutic applications. The company's corporate philosophy revolves around employing cutting-edge research and development to address unmet needs in the medical field. Arch Therapeutics Inc places great emphasis on collaboration with healthcare professionals, ensuring that their products meet the highest standards of efficacy and performance. With a strong dedication to improving patient outcomes, Arch Therapeutics Inc embodies values of excellence, integrity, and innovation in all aspects of their operations.

Arch Therapeutics Inc is primarily present in the United States. As a biotechnology company, Arch Therapeutics Inc focuses on developing innovative products to address unmet medical needs. With its headquarters located in Framingham, Massachusetts, the company primarily operates within the United States. By leveraging its proprietary self-assembling peptide technology platform, Arch Therapeutics Inc aims to revolutionize the field of wound healing and surgical adhesives. With a strong emphasis on research and development, the company is committed to advancing medical solutions that enhance patient outcomes and drive growth in the healthcare sector.

Arch Therapeutics Inc has achieved several significant milestones in recent years. One notable accomplishment is the completion of successful clinical trials for its flagship product, AC5 Topical Hemostat. This innovative hemostatic device has garnered attention and recognition from the medical community for its ability to rapidly control bleeding in both surgical and trauma settings. Arch Therapeutics Inc has also secured key partnerships and collaborations with leading healthcare organizations, further establishing its position in the market. Additionally, the company has received regulatory approvals and patents, highlighting its commitment to innovation and intellectual property protection. These achievements highlight Arch Therapeutics Inc's dedication to advancing medical solutions and improving patient outcomes.

Arch Therapeutics Inc is a biotechnology company based in the United States. Established in 2006, the company specializes in developing and commercializing novel medical devices. Arch Therapeutics is focused on addressing unmet clinical needs by providing innovative solutions for hemostasis and sealing in surgical and interventional medicine. With its flagship product, AC5 Advanced Wound System, the company aims to revolutionize surgical procedures by improving patient outcomes and reducing healthcare costs. Arch Therapeutics Inc has demonstrated a commitment to research and development, aiming to create groundbreaking healthcare solutions. Their dedication to innovation and advancement makes Arch Therapeutics Inc a prominent player in the biotechnology industry.

The main competitors of Arch Therapeutics Inc in the market include companies like Johnson & Johnson, Baxter International, and Medtronic.

Arch Therapeutics Inc is primarily active in the biotechnology and medical device industries.

The business model of Arch Therapeutics Inc revolves around the development and commercialization of novel wound healing and surgical products. This Massachusetts-based biotechnology company focuses on creating innovative solutions for the management of bleeding and fluid loss during surgical procedures. Arch Therapeutics aims to provide superior surgical tools and technologies to improve patient outcomes and enhance surgical performance. This company's dedication to advancing medical care through its cutting-edge products highlights its commitment to revolutionizing the field of surgical medicine.

Коефициентът на цена спрямо печалбата (КЦП) на Arch Therapeutics е 0,01.

Коефициентът на цена към оборот (KUV) на Arch Therapeutics е 0,01.

AlleAktien качественият резултат за Arch Therapeutics е 6/10.

очаквана Arch Therapeutics оборотът е 140,76 млн. USD.

очаквана Arch Therapeutics печалба е 112,18 млн. USD.

Arch Therapeutics is a biotechnology company that focuses on the development and marketing of therapeutic solutions for controlling bleeding and tissue formation. The company is headquartered in Framingham, Massachusetts and is listed on the Nasdaq stock exchange under the ticker symbol "ARTH".

Arch Therapeutics разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Arch Therapeutics в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Arch Therapeutics е US03939W1099.

WKN на Arch Therapeutics е A1W2JT.

Тикерът на Arch Therapeutics е ARTH.

През последните 12 месеца Arch Therapeutics изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Arch Therapeutics да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Arch Therapeutics в момента е .

Arch Therapeutics изплаща дивидент на тримесечие. Той се разпределя в месеците .

Arch Therapeutics платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Arch Therapeutics се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Arch Therapeutics на 21.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 21.09.2024 г..

Последното дивидентно плащане беше извършено на 21.09.2024 г..

През година 2023 Arch Therapeutics изплати 0 USD под формата на дивиденти.

Дивидентите от Arch Therapeutics се изплащат в USD.